How to Map the NF-κB Pathway and Choose Inhibitors: Bringing Inflammatory Transcriptional Output into a “Controllable Range” (Tables A–F)
How to Map the NF-κB Pathway and Choose Inhibitors: Bringing Inflammatory Transcriptional Output into a “Controllable Range” (Tables A–F)
1.The real-world problem: Why does inflammation often become “more complex the more you try to control it”?
In settings such as inflammation, autoimmunity, infection, and the tumor microenvironment, researchers often encounter the same phenomenon: for example, blocking a single cytokine or inhibiting a single receptor may initially drive biomarkers down and look effective. But after a while, inflammation returns—sometimes with a different set of molecules “taking over.” It’s like blocking one road: traffic quickly diverts to side routes. What looks like “flare-up” on the surface is often the system engaging alternative pathways (bypass compensation) to keep pushing inflammation forward.
A common reason is that inflammation is not a single linear chain, but more like a network: there are many upstream triggers (pathogen-associated signals, tissue-damage signals, cytokine cascades, etc.), and many downstream inflammatory genes can be turned on. In this network, the real trouble is often not “one specific line,” but the shared transcriptional hub that merges multiple inputs into a unified output—NF-κB. NF-κB is neither a single cytokine nor a single receptor; it is a family of transcription factors responsible for integrating stimuli from many immune/inflammatory receptors and launching a coordinated “inflammation/immune gene-expression program.”
When NF-κB is chronically or excessively activated, it often drives chronic inflammation and tissue damage, and in some tumors it can enhance cell survival and inflammatory crosstalk. However, NF-κB also participates in normal host defense and immune homeostasis: if you “shut NF-κB off completely,” you may introduce safety issues such as immunosuppression and increased infection risk.
Therefore, the more practical positioning of NF-κB inhibitors is often not “turn the switch off entirely,” but rather: at the right node, in the right disease/tissue context, within the right time window, reduce excessive NF-κB output—pulling inflammation back from ‘out of control’ into a ‘controllable’ range.
2.Core concepts: What is NF-κB? What does “NF-κB inhibitor” mean?
2.1 NF-κB: a transcriptional hub that “translates” multiple inflammatory inputs into gene expression
1. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is not a single molecule. It is a dimeric system formed by transcription factors of the Rel family. In mammals, the five commonly discussed members are RelA/p65, RelB, c-Rel, p50 (NF-κB1), and p52 (NF-κB2). Once activated, these factors translocate into the nucleus, bind κB sites in DNA, and thereby initiate/enhance the transcriptional output of a set of inflammation- and immunity-related genes.
2. Here, a κB site (κB binding site) refers to a class of DNA sequence elements that NF-κB can recognize and bind. The name and discovery history also come from this: NF-κB was first described because it binds a specific sequence within the enhancer of the immunoglobulin κ light-chain gene in B cells, and the “κB” designation has been retained ever since.
2.2 Two common meanings of “NF-κB inhibitor”
1. Broad sense (defined by outcome): Any intervention that reduces the output of NF-κB–dependent target genes may be called an NF-κB inhibitor—even if it does not directly act on a key node of the NF-κB axis.
2. Narrow sense (defined by mechanism): An intervention that acts on key steps of the NF-κB pathway and can explain why the output decreases—for example, by affecting IKK/IκB-related steps, nuclear translocation, DNA binding, or transcriptional activation.
2.3 How do you tell whether NF-κB is “truly inhibited”?
“A single inflammatory factor goes down” does not automatically mean “NF-κB is inhibited.” A more reliable approach is to cross-validate using readouts at different pathway levels:
Validation level (which step?) | Common readouts (what you can measure) | What it can tell you (key conclusion) | Common misinterpretations/pitfalls |
Initiation/release: is the release step blocked? (often in the canonical pathway) | Reduced IKK activation (e.g., p-IKK↓); reduced IκBα phosphorylation (p-IκBα↓); slower IκBα degradation / IκBα preserved | “NF-κB remains sequestered by IκBα; the initiation/release step is suppressed.” | IκBα is resynthesized via negative feedback (it is an NF-κB target gene). Readouts must be interpreted within a defined time window—avoid mistaking “rebound” for “loss of inhibition.” |
Nuclear entry: does less NF-κB actually enter the nucleus? | Reduced nuclear enrichment of p65/p50 (or RelB/p52) | “Nuclear translocation is inhibited; downstream transcriptional output will usually decrease.” | Less nuclear entry ≠ every target gene must decrease in lockstep (co-factors/bypass pathways can decouple outputs). |
Output: is NF-κB–dependent transcription globally weakened? | κB reporter activity↓; or coordinated downregulation of multiple κB target genes (do not look at only one factor) | “The functional, NF-κB–dependent output is indeed reduced.” | Focusing on a single factor can mislead; exclude “false decreases” caused by cytotoxicity or broad suppression of overall transcription. |
Note: Common NF-κB activation routes can be broadly divided into the canonical pathway (often IKK–IκBα–p65/p50, fast response) and the non-canonical pathway (often NIK–p100→p52–RelB, relatively slower response).
2.4 Why is NF-κB so often treated as a key control point?
NF-κB repeatedly appears in inflammation and immunology research and is frequently considered a potential intervention target for three main reasons:
1. Many upstream entry points: Many different stimuli converge on NF-κB (inflammatory cytokines, pathogen-associated signals, tissue damage and stress signals, etc.).
2. Large downstream impact: It directly drives an entire inflammation/immune gene-expression program, spanning cytokines, chemokines, adhesion molecules, and immune regulatory factors.
3. Balancing inhibition strength and scope: NF-κB also participates in normal immune defense and cell survival; therefore, strong, long-term, systemic inhibition often carries safety costs such as immunosuppression and elevated infection risk.
3.Pathway map: two common activation routes
When interpreting experimental readouts or discussing drug mechanisms, a more reliable practice is to first distinguish between the two common NF-κB activation axes: the canonical and non-canonical pathways. They differ in typical triggers, key molecular steps, time-to-effect, and the most sensitive validation readouts. If you do not separate them first, experiments can easily suffer from “wrong readout / poor sensitivity,” and mechanistic explanations can end up with “a broken causal chain.”
3.1 Canonical pathway: more like a “rapid inflammatory response”
A typical chain is: upstream stimulation (e.g., signaling from multiple inflammatory receptors) → activation of the IKK complex (often IKKβ-dependent) → IκBα is phosphorylated and undergoes proteasomal degradation → p65/p50 is released and translocates to the nucleus → transcription of pro-inflammatory genes is initiated.
3.2 Non-canonical pathway: more like “slow-variable regulation driven by specific receptors”
The non-canonical pathway is often triggered by certain TNFR family members (more constrained by receptor context). The core sequence is NIK stabilization → activation of IKKα → promotion of p100 processing to p52 → formation and nuclear entry of RelB/p52, which regulates transcription. It typically acts more slowly, but is more sustained.
4.Molecular modalities: NF-κB inhibitors do not share a “common core”—their form is determined by the mechanistic node
Many readers ask: Do NF-κB inhibitors share a common structural motif? In most cases, there is no single shared scaffold. This is because “NF-κB inhibitor” is better understood as a functional definition: as long as an intervention can suppress NF-κB–driven transcriptional output at a key node, it may fall into this category. Different nodes (kinases, complex assembly, nuclear entry/DNA binding, transcriptional output) naturally correspond to different molecular modalities: small molecules, peptides/peptidomimetics, and nucleic acids, among others.
Molecular modality | Pathway level most often targeted | Structural/chemical features | Advantages | Limitations and risks |
Small molecules: kinase-inhibitor type | Typically kinase nodes such as IKK/NIK (IKKβ is common in the canonical pathway; NIK/IKKα are more associated with the non-canonical pathway) | Classic “kinase inhibitor” heteroaromatic scaffolds; can bind the ATP site or an allosteric site | Clear node definition; enables systematic SAR optimization; well-established development path for PK and related properties | Selectivity and dose window are decisive: a broad kinase profile increases side effects and complicates interpretation |
Small molecules: covalent/electrophilic type | Often further downstream (e.g., affecting p65 DNA binding/transcriptional activity), and may impact multiple protein nodes simultaneously | Contain reactive “warheads” that can react with nucleophilic residues (e.g., Michael acceptors); some compounds show covalent engagement of key sites in Rel-family proteins | May “clamp” output directly at the downstream end—attractive when upstream inputs are complex and signaling redundancy is high | Off-pathway effects/cytotoxicity must be carefully monitored: electrophilic structures more readily show multi-target reactivity; typically require stronger mechanistic validation and safety assessment |
Peptides/peptidomimetics, oligonucleotides | PPI/assembly level or DNA-binding level: e.g., NBD peptide blocks NEMO–IKK assembly; NF-κB decoy ODN competes via a sequence “decoy” | Peptides/peptidomimetics disrupt protein–protein interactions; decoy ODNs compete using κB sequences for NF-κB binding | In principle, strong “directionality” with a more transparent mechanistic chain (block assembly or occupy DNA) | The main barriers are usually delivery, stability, and tissue distribution; in vivo use and translation are more challenging |
5.Classification: How to group NF-κB inhibitors by target node?
Category (by intervention node) | Point of action | Representative example(s) | Most relevant pathway branch | Typical use case | Limitations and risks |
IKK inhibitors | Inhibit IKK catalytic activity → reduced IκBα phosphorylation → less release/nuclear entry | BMS-345541 (allosteric inhibitor of IKK; can suppress NF-κB–dependent transcription) | Mainly canonical (IKKβ more typical; IKKα may also be affected) | Mechanistic validation; “turn down” canonical NF-κB output in inflammatory models | Selectivity and dose window are critical (kinase spectrum/off-target profile often determines success) |
Block IKK complex assembly (PPI) | Disrupt assembly/binding between NEMO (IKKγ) and IKK | NBD peptide (cell-permeable peptide that blocks NEMO–IKK interaction) | Mainly canonical (NEMO-dependent) | Mechanistic validation that separates “assembly/activation” from upstream stimuli | Strong dependence on delivery, stability, and cell type; higher barriers for in vivo translation |
Proteasome/degradation-step interference (broad) | Proteasome inhibition affects degradation of proteins such as IκBα (thus altering NF-κB dynamics) | Bortezomib: often used to modulate NF-κB, but not specific | Context-dependent (can suppress NF-κB, but may also produce different directional dynamics) | More often used to test whether NF-κB contributes to a phenotype; common in tumor-related research | Very broad mechanism; NF-κB readouts may be inconsistent across samples/contexts—use layered evidence for cross-validation |
Key non-canonical node: NIK inhibitors | Inhibit NIK → reduced p100→p52 processing → weakened RelB/p52 output | B022 and other NIK tool compounds (block p100→p52 processing and non-canonical output) | Mainly non-canonical (NIK–IKKα–p100/p52–RelB) | Mechanistic dissection when a “slow-variable/specific TNFR-family context” suggests a non-canonical driver | Non-canonical kinetics are slower and require different time windows; do not rely on rapid IκBα degradation as the sole indicator |
Downstream clamping (DNA binding / nuclear function layer) | Covalently engages key residues in Rel-family components to reduce DNA-binding activity (often also manifests as reduced nuclear function/translocation readouts in many models) | (−)-DHMEQ: covalently binds specific cysteines in Rel-family proteins, inhibits DNA binding, and often limits nuclear translocation/nuclear function | Targets the “transcription factor end,” potentially affecting Rel components involved in both canonical and non-canonical branches (e.g., p65/p50, RelB) | When upstream inputs are complex and bypass compensation is prominent: test whether directly lowering the NF-κB output end can broadly reduce κB target gene expression; often used as a mechanistic control | Covalent/reactive mechanisms require close attention to selectivity, off-target effects, and toxicity window; typically pair with layered mechanistic evidence and safety readouts to define a usable dose range |
κB-site “decoy” (Decoy ODN) | Double-stranded oligonucleotides containing κB sites compete for NF-κB binding, reducing occupancy at true target genes | NF-κB decoy ODN: investigated in skin inflammation models (e.g., atopic dermatitis) and local-delivery strategies | Output end (independent of which upstream route is active) | Best suited to local, delivery-controllable inflammatory settings (skin, localized tissues) | Delivery, stability, immunogenicity, and tissue distribution are key barriers |
6.Three application storylines: Where are NF-κB inhibitors commonly used, and what problems do they solve?
Application setting | Core problem being addressed | Practical use points |
Inflammation and autoimmunity research | When a whole panel of inflammatory genes/factors is up: is NF-κB driving an “inflammatory transcriptional program”? | Use as a causal validation tool: after inhibition, assess whether a set of κB target genes / an inflammatory signature drops as a whole—don’t fixate on a single cytokine; ideally add a nuclear-entry readout or an IκB/IKK readout to complete the mechanistic chain |
Cancer and the tumor microenvironment | Phenotypes such as survival, anti-apoptosis, resistance/invasion: are they maintained by NF-κB output? | Use for mechanistic dissection: after inhibiting NF-κB, evaluate phenotypic changes (survival/resistance/migration) together with reduced κB output to argue dependence on NF-κB, rather than nonspecific toxicity or broad inhibition |
Infection and host–pathogen interactions | Is inflammation helping pathogen clearance, or mainly driving tissue damage/chronicity? | Distinguish protective vs damaging inflammation by tracking three things simultaneously after inhibition/modulation: pathogen burden/clearance, tissue damage markers, and inflammatory signatures/κB target genes; focusing only on decreased inflammatory factors can easily lead to the wrong conclusion |
7.NF-κB Inhibitor Product Navigation: Quickly Map “Research Task / Experimental Readout” to Tables A–F
Research task / experimental need | Typical stimuli / models | Primary readouts (recommended combinations) | Tables to check first | Selection notes |
1) Pathway mapping: Determine whether NF-κB is driven by “upstream inputs” (TLR/IL-1R/TNFR → TAK1) | LPS, TNF-α, IL-1β; macrophages/monocytes/epithelial cells | p-IKK, p-IκBα, IκBα degradation; p65 nuclear translocation; NF-κB luciferase | Table A + Table B | Table A provides probes at the upstream hub (TAK1); Table B provides IKK-end controls. Using both helps distinguish an “upstream input problem” vs an “IKK-end problem.” |
2) Pathway mapping: Distinguish canonical vs non-canonical NF-κB (NIK–IKKα–p100→p52/RelB) | BAFF, CD40, LTβR, etc.; B cells/immune cells | p100→p52 processing; RelB/p52 nuclear localization; (in parallel) p65 nuclear translocation | Table A (priority) + Table B (supporting) | Table A includes NIK probes and is best suited for non-canonical mapping; if needed, use Table B IKK inhibitors as “shared downstream node” controls. |
3) Core node validation: Prove output depends on IKKβ (key node in canonical pathway) | TNF-α / IL-1β / LPS stimulation models | p-IκBα/IκBα; p65 nuclear translocation; NF-κB reporter; inflammatory cytokines by qPCR/ELISA | Table B (priority) | Table B concentrates IKKβ/IKK inhibitors—most direct for validating “IKKβ dependence” and establishing pharmacologic benchmarks. |
4) Mechanistic dissection: Where is the bottleneck—IκBα phosphorylation vs ubiquitination vs proteasomal degradation? | TNF-α / LPS; requires protein turnover / ubiquitination mechanisms | IκBα stabilization; Ub-IκBα accumulation; proteasome activity; (in parallel) p65 nuclear translocation | Table D (priority) + Table B/Table C (cross-validation) | Table D covers proteasome, NAE/NEDD8, and IκB ubiquitination blockade—refines the site from “upstream kinases” to “which step in the degradation machinery.” Tables B/C help exclude “it’s actually the IKK end / nuclear-entry end.” |
5) Fast strong positive control: Need a control that “immediately suppresses NF-κB” for screening/system setup | Any activation model; HTS hit confirmation | NF-κB luciferase; p65 nuclear translocation; inflammatory cytokines | Table C (priority) | Table C concentrates “terminal / nuclear-entry / transcriptional output” inhibitors (including strong positives), ideal for quickly verifying the assay system and confirming screening hits. |
6) Terminal validation: Only care whether “NF-κB output decreases” (not aiming for single-target mapping) | Inflammatory stimulation models; PD validation | NF-κB reporter; inflammatory cytokines by qPCR/ELISA | Table C + Table E (as needed) | Table C provides probes acting directly at the output layer; Table E provides commonly used natural-product positive controls—useful for comparing “functional endpoint reduction.” |
7) Natural products / polyphenols / terpenoids: Want classic natural controls or structure–activity comparisons | LPS/TNF-α inflammatory models; oxidative stress–inflammation coupling | NF-κB reporter; p65 nuclear translocation; ROS/cell viability; inflammatory cytokines | Table E (priority) | Table E concentrates multi-target natural products—suited for “natural controls / multi-pathway coupling.” Run cell viability and ROS in parallel to avoid miscalling state-dependent suppression. |
8) Pharmacology benchmarking: Need clinical anti-inflammatory / immunosuppressive drugs as “real-world controls” | Cellular inflammation models; efficacy benchmarking | Inflammatory cytokines by qPCR/ELISA; (optional) NF-κB reporter | Table F (priority) | Table F focuses on clinical comparators—best for “functional endpoint benchmarking,” but usually not for fine pathway mapping. |
9) Want to separate “upstream blockade” vs “nuclear entry/transcription-end blockade” | Any NF-κB activation model | Measure together: p-IκBα/IκBα (upstream) + p65 nuclear translocation (nuclear-entry layer) + reporter (output) | Table B + Table C | Table B targets the IKK/IκB axis; Table C targets nuclear entry/output. Side-by-side controls make the mapping very clear. |
10) System abnormality: Inhibition looks strong, but you worry it’s due to “cell state/toxicity” | Cell death/stress occurs under stimulation | Cell viability/toxicity; ROS; stress markers; NF-κB readouts in parallel | Avoid using Table E / parts of Table C alone; switch to Table B/Table A for cross-validation | Natural products and some strong inhibitors may come with stress/toxicity. Cross-validating with mapping probes in Table A/B can markedly reduce false calls. |
Table A | Upstream Kinase-Axis Inhibitors (TAK1 / NIK; for Mapping Canonical vs Non-canonical NF-κB)
Category | CAS No. | Aladdin No. | Name | Specification / Purity | Product features & applications |
Upstream kinase inhibitor | TAK1/MAP3K7 (upstream hub of canonical NF-κB) | 1111556-37-6 | Takinib, TAK1/MAP3K7 kinase inhibitor | Moligand™, ≥98% (HPLC) | Used to block upstream signaling through TAK1 → IKK/NF-κB (also affects JNK/p38 in parallel). Common readouts: p-IKK/p-IκBα, p65 nuclear translocation, NF-κB reporter activity, and decreased inflammatory-gene transcription—used to test whether NF-κB is driven by the TAK1 axis. | |
Upstream kinase inhibitor | TAK1/MAP3K7 (canonical NF-κB upstream) | 1315355-93-1 | NG25, TGF-β-activated kinase (TAK1) inhibitor | Moligand™, ≥98% | TAK1 inhibitor commonly used to block upstream inputs from TLR/IL-1R/TNFR into IKK/NF-κB. Readouts include reduced p-IKK/p-IκBα, p65 nuclear translocation, and NF-κB reporter activity. Recommended to run in parallel with an IKKβ inhibitor to distinguish “upstream input” vs “IKK-end” contributions. | |
Upstream kinase inhibitor | TAK1/MAP3K7 (commonly used probe) | 253863-19-3 | (5Z)-7-Oxozeaenol | Moligand™, ≥98% | Widely used TAK1 probe to block upstream inputs from TLR/IL-1R/TNFR into IKK/NF-κB. Readouts: reduced p-IKK/p-IκBα, p65 nuclear translocation, and inflammatory-gene expression. Recommended to use dose/time gradients and confirm with a second probe to strengthen mechanistic interpretation. | |
Upstream kinase inhibitor | NIK (non-canonical NF-κB pathway) | 1202764-53-1 | B022 | ≥99% | NIK inhibitor probe for non-canonical NF-κB models (e.g., BAFF/CD40/LTβR). Used to assess decreased p100→p52 processing and reduced RelB/p52 axis outputs (nuclear localization/target genes), helping separate canonical vs non-canonical contributions. | |
Upstream kinase inhibitor | NIK (non-canonical NF-κB pathway probe) | 1660114-31-7 | NIK SMI1 | Moligand™, ≥98% | Probe for the non-canonical NF-κB pathway (NIK–IKKα–p100→p52/RelB). Commonly used in BAFF/CD40/LTβR stimulation models; readouts include p100 processing to p52 and RelB nuclear localization, to distinguish canonical/non-canonical NF-κB contributions. |
Table B | IKK Complex Inhibitors (IKKβ / Pan-IKK / IKKα+β; Core Mapping for the Canonical Pathway)
Category | CAS No. | Aladdin No. | Name | Specification / Purity | Product features & applications |
IKK complex inhibitor | Selective IKKβ inhibition (canonical chemical probe) | 960293-88-3 | BI 605906, IKKβ inhibitor | Moligand™, ≥98% (HPLC) | A representative IKKβ chemical probe: in TNF-α/IL-1β/LPS systems, blocks IκBα phosphorylation/degradation, suppresses p65 nuclear translocation and NF-κB reporter activity; suitable for validating “IKKβ dependence” and pathway-mapping controls. | |
IKK complex inhibitor | IKKβ inhibition (common control) | 783348-36-7 | MLN120B, IκB kinase β (IKKβ) inhibitor | Moligand™, ≥98% | Common IKKβ inhibitor control: suitable for TNF-α/IL-1β/LPS models to block IκBα phosphorylation and reduce NF-κB reporter signals; used for “IKKβ dependence” validation and efficacy benchmarking. | |
IKK complex inhibitor | IKKβ (IKK2) inhibition | 507475-17-4 | TPCA-1, IκB kinase inhibitor | Moligand™, ≥98% | Common IKKβ inhibitor: suppresses IκBα phosphorylation/degradation, p65 nuclear translocation, and NF-κB-dependent cytokine expression (IL-6/IL-8/TNF-α) in inflammatory stimulation models; used for pathway mapping and PD controls. | |
IKK complex inhibitor | IKKβ inhibition (common control) | 978-62-1 | IMD 0354, IKKβ inhibitor | ≥99% | IKKβ inhibitor control: commonly used to block IκBα phosphorylation and reduce NF-κB-dependent inflammatory gene expression (qPCR/ELISA, reporter assays) in stimulated inflammation models. | |
IKK complex inhibitor | Selective IKKβ inhibition | 600734-06-3 | Bay 65-1942 hydrochloride | ≥99% | Selective IKKβ inhibitor: commonly used in TNF-α/IL-1β/LPS models to block IκBα phosphorylation/degradation and p65 nuclear translocation; suitable for “IKKβ-end pathway mapping” controls (WB: p-IκBα/IκBα; reporter/cytokine readouts). | |
IKK complex inhibitor | Allosteric IKK inhibition (canonical pathway-mapping probe) | 547757-23-3 | BMS-345541, allosteric inhibitor of IKK | Moligand™, ≥98% | Canonical allosteric IKK inhibitor: helps distinguish “IKK-dependent canonical NF-κB activation” from parallel pathways; often paired with WB (p-IκBα/IκBα) + NF-κB reporter / nuclear translocation for mechanistic mapping. | |
IKK complex inhibitor | Dual IKKα/IKKβ inhibition | 406208-42-2 | ACHP, IKKα and IKKβ inhibitor | ≥97% (HPLC) | Blocks NF-κB activation associated with both IKKα/β: useful for comparing canonical readouts (p-IκBα/IκBα, p65 nuclear translocation) and some non-canonical-related readouts to assess IKK isoform contributions; commonly used as a “dual IKK inhibition” mapping control. | |
IKK complex inhibitor | IKK inhibition (IKK-16, common positive control) | 873225-46-8 | IKK-16 (IKK inhibitor VII) | ≥99% | Common IKK inhibitor: rapidly suppresses canonical NF-κB activation (IκBα phosphorylation/degradation, p65 nuclear translocation, NF-κB reporter activity); suitable for mechanistic dissection and positive control. | |
IKK complex inhibitor | IKK inhibition (IKK-16) | 1186195-62-9 | IKK-16, IκB kinase inhibitor | ≥98% | Common IKK inhibitor: blocks canonical NF-κB activation (IκBα phosphorylation/degradation, p65 nuclear translocation); suitable for pathway mapping and positive control. | |
IKK complex inhibitor | IKK inhibition (common positive control) | 1049743-58-9 | PS-1145 dihydrochloride | Moligand™, ≥98% | Selective IKK inhibitor: commonly used to suppress IκBα phosphorylation and NF-κB activation (reporter assays, p65 nuclear translocation, cytokine transcription/secretion); suitable as an “IKK-axis blockade” positive control. | |
IKK complex inhibitor | IKK inhibition (PS-1145) | 431898-65-6 | PS-1145 | ≥98% | IKK inhibitor control: commonly used to suppress IκBα phosphorylation and NF-κB reporter signals, validating “IKK-axis dependence” of inflammatory outputs (IL-6/TNF-α, etc.). | |
IKK complex inhibitor | IKKβ (IKK2) inhibition | 354812-17-2 | SC-514 | ≥98% | IKKβ inhibitor: commonly used in TNF-α/LPS models for p-IκBα/IκBα, p65 nuclear translocation, and NF-κB reporter readouts as an IKKβ-axis blockade control. (Note: in practice, can be cross-validated with BI 605906 / TPCA-1.) |
Table C | Inhibitors Acting at the IκB Phosphorylation / Nuclear Translocation / Transcriptional Output Layer (Commonly Used for Terminal Validation and Mechanistic Dissection)
Category | CAS No. | Aladdin No. | Name | Specification / Purity | Product features & applications |
IKK/IκB-axis inhibitor | Rapid blockade of canonical NF-κB activation (strong positive control) | 19542-67-7 | BAY 11-7082, IκBα kinase inhibitor | Moligand™, ≥98% | A classic “rapid, strong-positive” NF-κB inhibitory control: commonly used in TNF-α/LPS stimulation models to inhibit IκBα phosphorylation, thereby reducing p65 nuclear translocation and downstream inflammatory gene expression. However, this compound is relatively reactive and is known to have multi-target/irreversible effects; for mechanistic interpretation, cross-validate with more selective IKKβ/TAK1 inhibitors. | |
IKK/IκB-axis inhibitor | Inhibits IκBα phosphorylation (irreversible, strong positive control) | 196309-76-9 | Bay 11-7085, irreversible inhibitor of TNF-α–induced IκBα phosphorylation | ≥98% (HPLC) | A classic “rapid, strong-positive” NF-κB inhibitory control: commonly used in TNF-α/LPS stimulation models to irreversibly inhibit IκBα phosphorylation, weakening p65 nuclear entry/translocation and lowering downstream inflammatory factor expression. Because reactivity and multi-target effects may occur, cross-validate with more selective IKK or TAK1 inhibitors when interpreting mechanisms. | |
NF-κB nuclear-entry inhibitor | Blocks p65 nuclear translocation (JSH-23) | 749886-87-1 | 4-Methyl-N1-(3-phenylpropyl)-1,2-benzenediamine | ≥98% (HPLC) | JSH-23 (NF-κB activation inhibitor II): selectively blocks p65 nuclear translocation and downstream transcriptional output. Often used to confirm reduced p65 nuclear entry by IF/nuclear fractionation, together with NF-κB reporter and cytokine readouts; a standard “nuclear-translocation-layer” mapping probe. | |
Direct NF-κB inhibitor | Terminal output suppression (strong positive) | 545380-34-5 | QNZ (EVP4593), NF-κB inhibitor | Moligand™, ≥98% | Commonly used as a potent NF-κB inhibitory control: suitable for validating suppression in NF-κB luciferase, p65 nuclear translocation, and downstream inflammatory gene expression. Its mechanism is more likely to act at upstream signaling steps (rather than directly targeting IKK or NF-κB itself); use primarily as a “strong positive / screening confirmation” rather than a single-target mapping tool, and run cell viability/toxicity readouts in parallel to exclude state-dependent decreases. | |
Direct NF-κB output inhibitor | DHMEQ family (blocks p65/Rel nuclear entry/transcription) | 287194-41-6 | (+)-DHMEQ | ≥99% | Widely used chemical probe for “direct suppression of NF-κB output”: covalently engages Rel-family components and inhibits DNA-binding activity. Common readouts include NF-κB luciferase, κB target-gene expression, and (often accompanying) changes in p65 nuclear translocation. Pair DNA-binding/reporter assays with cell viability (toxicity window) to support mechanistic interpretation. | |
Direct NF-κB output inhibitor | DHMEQ family (blocks p65/Rel nuclear entry/transcription) | 287194-40-5 | (−)-DHMEQ | ≥98% | Same DHMEQ family as (+)-DHMEQ: covalently binds Rel-family proteins and inhibits DNA binding. Used in NF-κB reporter assays, κB target genes, and (often accompanying) p65 nuclear translocation readouts; recommended to run dose–time gradients and parallel cell viability/toxicity windows. | |
Direct NF-κB output inhibitor | DHMEQ racemate | 287194-38-1 | DHMEQ racemate | _ | Racemic DHMEQ: inhibits Rel-family DNA binding via covalent action; used for NF-κB output suppression validation (reporter assays, κB target genes; nuclear translocation often as a supportive readout). Suitable as an overall DHMEQ-family comparator or for screening confirmation; run cell viability in parallel to exclude state-dependent decreases. | |
Toxin / fungal metabolite | NF-κB inhibition (often accompanied by cellular stress/toxicity) | 67-99-2 | Gliotoxin | ≥99% | One commonly used NF-κB inhibitory control: can be used to observe IκBα stabilization, reduced p65 nuclear translocation, and decreased NF-κB–dependent inflammatory cytokine expression. Run cell viability/toxicity and ROS/stress readouts in parallel to avoid mistaking “state-dependent suppression” for mechanistic inhibition. | |
Natural product / sesquiterpene lactone | Directly targets p65 (inhibits DNA binding; often reactive) | 6754-13-8 | Helenalin | _ | Helenalin-class sesquiterpene lactone: can directly interfere with p65 DNA binding/transcriptional output; commonly used for NF-κB DNA-binding/reporter/cytokine suppression validation. Due to electrophilicity and higher multi-target risk, use dose–toxicity windows and time gradients, and cross-validate with IKKβ/TAK1 probes. | |
Transcription inhibitor | Suppresses AP-1 / NF-κB–mediated transcription (transcription-layer control) | 219773-55-4 | 1-(5-Methoxy-2-thiophen-2-yl-quinazolin-4-ylamino)-3-methyl-pyrrole-2,5-dione | _ | Used to inhibit AP-1 and NF-κB–mediated transcriptional activation: commonly used as a “transcription-layer inhibition” control and for screening confirmation in NF-κB reporter/inflammation models. Run cell viability and upstream pathway readouts (p-IκBα/IκBα, p65 nuclear translocation) in parallel to distinguish “transcriptional suppression” from “upstream blockade.” |
Table D | Protein Homeostasis / Ubiquitin-System Modulation (Proteasome / NAE–NEDD8 / IκB Ubiquitination)
Category | CAS No. | Aladdin No. | Name | Specification / Purity | Product features & applications |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor (affects IκB degradation) | 868540-17-4 | Carfilzomib | Moligand™, ≥99% | Irreversible proteasome inhibitor; commonly used to validate the “proteasome-dependent IκBα degradation → NF-κB activation” chain (WB: IκBα stabilization, reduced p65 nuclear translocation; can be paired with proteasome activity and ubiquitination-accumulation readouts). | |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor (blocks IκBα degradation) | 133343-34-7 | Lactacystin | Moligand™ ≥98% | Classic irreversible proteasome inhibitor: used to validate dependence on “proteasome-mediated IκBα degradation → NF-κB activation.” Readouts include IκBα stabilization, reduced p65 nuclear translocation, decreased NF-κB reporter activity; run cell viability/stress readouts in parallel. | |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor (epoxyketone class, high potency) | 134381-21-8 | Epoxomicin | ≥97% | Potent proteasome inhibitor: commonly used to block IκBα degradation and thereby inhibit NF-κB activation; can be paired with proteasome activity and ubiquitinated-protein accumulation readouts; run cell viability and stress markers in parallel. | |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor (affects IκB degradation) | 133407-82-6 | MG-132, reversible proteasome inhibitor | Moligand™, ≥98% | Classic reversible proteasome inhibitor: used to test whether IκBα degradation is required for NF-κB activation (IκBα stabilization; reduced p65 nuclear translocation/reporter activity). Also widely used for ubiquitinated-protein accumulation and protein-degradation mechanism studies (recommended to cross-validate with a second proteasome inhibitor or activity assays). | |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor (affects IκB degradation) | 133407-86-0 | MG-115, reversible proteasome inhibitor | Moligand™, ≥95% | Reversible proteasome inhibitor: used to test the link between IκBα degradation and NF-κB activation (IκBα stabilization; reduced p65 nuclear translocation/reporter activity). Compounds in this class can show concurrent protease inhibition; cross-validate with another proteasome inhibitor. | |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor (affects IκB degradation) | 1072833-77-2 | Ixazomib (MLN2238) | Moligand™, ≥98% | Proteasome inhibitor: used to suppress IκBα degradation and reduce NF-κB activation; suitable for validating “protein-homeostasis intervention → NF-κB output changes,” and can be read alongside proteasome activity/apoptosis indicators. | |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor prodrug (MLN9708 / ixazomib citrate) | 1201902-80-8 | Ixazomib citrate (MLN9708) | ≥98% | Proteasome inhibitor (ixazomib prodrug): used to inhibit IκBα degradation, reduce NF-κB nuclear translocation, and lower downstream inflammatory/survival gene expression; suitable for mechanistic validation of “protein-homeostasis intervention → NF-κB output,” and can be paired with proteasome activity/ubiquitinated-protein accumulation. | |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor prodrug (MLN9708 / ixazomib citrate) | 1239908-20-3 | Ixazomib citrate (MLN9708) | ≥97% | Same MLN9708 (citrate salt) as above: used for experiments linking proteasome inhibition → IκBα stabilization → reduced NF-κB output (reporter assays / nuclear translocation / cytokines); suitable as a “protein-homeostasis intervention” control. | |
Protein homeostasis / ubiquitin-system modulation | NAE/NEDD8 inhibition (indirectly affects NF-κB at the CRL layer) | 905579-51-3 | MLN4924, NEDD8-activating enzyme inhibitor | Moligand™, ≥98% | NAE inhibitor: alters inflammatory signaling output by blocking neddylation/CRL-related protein turnover; commonly used for dissecting “ubiquitin-system–inflammation/NF-κB” coupling mechanisms (can be read alongside CRL substrate accumulation, IκBα turnover, NF-κB reporter activity, and cytokines). | |
IκBα ubiquitination inhibitor | Blocks IκBα ubiquitination/degradation | 62645-28-7 | 6-(Phenylsulfonyl)tetrazolo[1,5-b]pyridazine (Ro 106-9920) | ≥95% | Classic probe that “blocks IκBα ubiquitination/degradation → inhibits NF-κB activation”: suitable for validating IκBα stabilization, decreased NF-κB reporter activity, and reduced NF-κB–dependent cytokine expression; helps further localize the action point to the ubiquitination step, beyond “IKK phosphorylation” vs “proteasomal degradation.” | |
Protein homeostasis / ubiquitin-system modulation | Proteasome inhibitor (boronic acid class; affects IκBα degradation) | 179324-69-7 | Bortezomib (PS-341) | Moligand™, ≥98% | Reversible proteasome inhibitor (boronic acid class): commonly used to validate dependence on “proteasome-mediated IκBα degradation → NF-κB activation.” Typical readouts include IκBα stabilization (WB), reduced p65 nuclear translocation (IF/nuclear fractionation), and decreased NF-κB reporter activity / cytokines (qPCR/ELISA); can also be paired with ubiquitinated-protein accumulation and proteasome-activity assays to support mechanistic interpretation. |
Table E | Multi-target NF-κB Modulation by Natural Products / Polyphenols / Terpenoids (Common Positive Controls)
Category | CAS No. | Aladdin No. | Name | Specification / Purity | Product features & applications |
Natural product / polyphenol | Multi-target NF-κB downregulation (common positive control) | 458-37-7 | Curcumin | Synthetic, Moligand™, ≥98% | One of the classic “NF-κB downregulation” positive controls: commonly used in TNF-α/LPS/IL-1β stimulation models with paired readouts of p-IκBα/IκBα, p65 nuclear translocation (IF/nuclear fractionation), NF-κB luciferase, and cytokines (IL-6/TNF-α) by qPCR/ELISA. Strong multi-target/antioxidant effects; recommended to pair with selective IKK/TAK1 probes for pathway mapping. | |
Natural product / polyphenol | Multi-target NF-κB downregulation (common positive control) | 501-36-0 | Resveratrol | Moligand™, ≥99% | Common NF-κB downregulation control in oxidative-stress/inflammation models; suitable for NF-κB reporter assays, p65 nuclear translocation, and downstream inflammatory genes (IL-6, COX-2, iNOS). When multiple pathways run in parallel (SIRT1/AMPK/ROS, etc.), pair with an IKKβ inhibitor as a mapping control. | |
Natural product / tea polyphenol | Multi-target NF-κB downregulation (antioxidant–inflammation coupling) | 989-51-5 | (−)-Epigallocatechin gallate (EGCG) | Moligand™, ≥98% | Common control in LPS-stimulated macrophage/monocyte models: NF-κB reporter, p65 nuclear translocation, and cytokines (TNF-α/IL-1β/IL-6). Strong antioxidant/membrane effects; run ROS/cell viability in parallel to distinguish state-dependent suppression. | |
Natural product / flavonoid | Multi-target NF-κB downregulation (common positive control) | 117-39-5 | Quercetin | Moligand™, ≥95% | Common flavonoid control: suitable for NF-κB reporter assays, p65 nuclear translocation, and downstream cytokine expression in inflammatory stimulation models. Often involves antioxidant/kinase-network effects; for mechanistic mapping, cross-validate with selective IKKβ/TAK1 inhibitors. | |
Natural product / plant lactone | Multi-target NF-κB downregulation (common positive control) | 524-12-9 | Wedelolactone | Moligand™, ≥98% (HPLC) | Common in “natural product inhibition of NF-κB” research; in TNF-α/LPS models, used with readouts of IκBα phosphorylation/degradation, p65 nuclear translocation, and NF-κB reporter suppression. Potential multi-target/electrophilic effects; recommend dose–toxicity window and time gradients. | |
Natural product / diterpene lactone | Multi-target NF-κB downregulation (common positive control) | 5508-58-7 | Andrographolide | Moligand™, ≥98% | Commonly used to suppress NF-κB activation in LPS/TNF-α inflammation models: can be read via IκBα degradation/phosphorylation, p65 nuclear translocation, NF-κB reporter activity, and paired cytokine downregulation. | |
Natural product / phenolic ester | NF-κB downregulation (CAPE, common positive control) | 104594-70-9 | Caffeic acid phenethyl ester (CAPE) | ≥97% | Classic natural-product NF-κB inhibitory control: often used to suppress stimulus-induced NF-κB reporter activity and p65 nuclear translocation, with paired cytokine downregulation (IL-6/TNF-α, etc.). Multi-target/electrophilic effects may exist; run dose–toxicity windows in parallel. | |
Natural product / diterpene | Anti-inflammatory NF-κB downregulation (multi-target control) | 28957-04-2 | Oridonin | ≥98% | Commonly used to reduce NF-κB output in inflammation/immune models (NF-κB reporter, p65 nuclear translocation, cytokine expression). Multi-target/electrophilic effects may be stronger; run cell viability and dose windows in parallel to avoid mistaking cell-state shifts for pathway inhibition. | |
Natural product / triterpene | Potent multi-target suppression (often with stress/proteostasis effects) | 34157-83-0 | Celastrol | Moligand™, ≥98% | Potent natural-product inhibitor: commonly used for NF-κB reporter and cytokine readouts. Because it can strongly affect cellular stress/protein homeostasis, run cell viability/toxicity and heat-shock/UPS indicators in parallel to avoid interpreting “state-dependent suppression” as pure pathway inhibition. | |
Natural product / diterpene lactone | Potent immunosuppression/anti-inflammation (NF-κB downregulation) | 38748-32-2 | Triptolide | ≥98% | Potent natural-product control: commonly used for NF-κB reporter assays, p65 nuclear translocation, and cytokine downregulation. Strictly define dose–toxicity windows and time gradients, and run cell viability/stress readouts in parallel to avoid mistaking cytotoxicity for pathway inhibition. | |
Natural product / anthraquinone | NF-κB downregulation (common control) | 518-82-1 | Emodin | ≥90% (HPLC) | Common anthraquinone control: can be used in stimulated inflammation models to observe reduced NF-κB reporter activity, p65 nuclear translocation, and cytokine expression. Run cell viability/ROS and related readouts in parallel to avoid mistaking oxidative stress/toxicity–driven “state changes” for pathway inhibition. |
Table F | Clinical Anti-inflammatory / Immunomodulatory Comparator Drugs (Primarily for Functional Endpoint Benchmarking)
Category | CAS No. | Aladdin No. | Name | Specification / Purity | Product features & applications |
Clinical anti-inflammatory comparator | NSAID (functional endpoint control; not an NF-κB-specific probe) | 50-78-2 | Acetylsalicylic acid (Aspirin) | Moligand™, for plant cell culture, ≥99% | Common anti-inflammatory comparator: in stimulated inflammation systems, can be used to observe reduced NF-κB–related inflammatory outputs at the “functional endpoint” level (qPCR/ELISA), but it is not specific to NF-κB/IKK. For mechanistic interpretation, treat as a pharmacologic comparator/background reference. | |
Clinical anti-inflammatory / immunomodulatory | Non-acetylated salicylate (IKKβ/NF-κB–related; functional comparator) | 552-94-3 | Salsalate | ≥98% | Anti-inflammatory comparator: often used as an IKKβ–NF-κB axis intervention reference in metabolic inflammation/immune inflammation models. Suitable for cytokine endpoints (qPCR/ELISA) and NF-κB reporter confirmation, but not for single-target pathway mapping. | |
Clinical anti-inflammatory / immunomodulatory | Immuno-inflammatory comparator (commonly referenced for NF-κB downregulation) | 599-79-1 | Sulfasalazine | Moligand™, ≥98% | Common comparator in inflammation/immune research: often used in stimulation models to reduce NF-κB–related inflammatory gene expression and cytokine release. Suitable for functional endpoints (qPCR/ELISA) and NF-κB reporter confirmation, but the mechanism is not a single-target mapping tool. | |
Clinical anti-inflammatory / immunomodulatory | Glucocorticoid (GR-mediated transrepression of NF-κB) | 53-03-2 | Prednisone | Moligand™, ≥98% | Classic immunosuppressive/anti-inflammatory comparator: suppresses NF-κB–dependent inflammatory gene expression through GR-mediated transcriptional regulation. Commonly used as a “pharmacologic comparator group” for reduced cytokines (IL-6, TNF-α), primarily for functional endpoint benchmarking rather than pathway mapping. | |
Clinical anti-inflammatory / immunomodulatory | Glucocorticoid (GR-mediated transrepression of NF-κB) | 50-02-2 | Dexamethasone | BioReagent, for cell culture, Moligand™, ≥97%, powder | One of the most commonly used anti-inflammatory positive controls in cell models: suppresses NF-κB–dependent inflammatory genes via GR-mediated transcriptional regulation. Often used as an efficacy benchmark for reduced cytokines (IL-6/TNF-α, etc.) by qPCR/ELISA and decreased NF-κB reporter activity—primarily a “functional endpoint control,” not a pathway-mapping probe. |
Note: The above are representative Aladdin products. For additional specifications, please refer to the product list at the end of the document, or search the Aladdin website using “product name / CAS / catalog number.”
For more related articles, please see below:
LPS-Induced Cellular Inflammation Model: Experimental Procedure
Activation and monitoring of inflammatory vesicles